🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thanks for hosting me today! It was great to hear about all of the exciting liquid biopsy research happening U-M Rogel Cancer Center, catch up with old friends, and make new friends!

Thank you to Max Diehn, MD/PhD for an insightful talk today on liquid biopsies for cancer detection and characterization. Our medical residents and faculty enjoyed a great dinner last night as well! We hope you enjoyed your visit to our department!

NCCN Guidelines for DLBCL now include ctDNA MRD testing. This is a major advance for patients and the liquid biopsy field. Congrats to the Foresight Diagnostics team for this significant achievement!

In nature from Stanford Medicine by Max Diehn, MD/PhD & Ash Alizadeh, MD/PhD 🇺🇸 An ultrasensitive method for detection of cell-free RNA nature.com/articles/s4158… RARE-seq has a limit of detection of 0.05%, identifies ~30% of stage 1 lung cancers, and provides information on resistance mechanisms.

Our study integrating ctDNA & radiomics to predict outcomes in NSCLC treated with CRT is online at Cancer Discovery! A great collaboration between Steven H. Lin MD Anderson Cancer Center and the labs of Max Diehn, MD/PhD, Ash Alizadeh, MD/PhD 🇺🇸, & Ruijiang Li Stanford Radiation Oncology. 🧵(1/11) doi.org/10.1158/2159-8…